PROJECT

Overview

HORUS involves the first longitudinal cohort of European SOT recipients. In a sub-‘HORUS-exploratory cohort’, we will perform a thorough investigation of viral, clinical and immunological characteristics. 

Combining those parameters will provide a signature early after transplantation to predict the risk of developing CMV infection and a signature at Day 0 of infection to predict the risk of CMV disease severity.

This signature will then be validated retrospectively by the whole cohort and prospectively in a ‘proof-of-concept’ study. Moreover, HORUS will include functional in vitro and mouse models to investigate the mechanisms of lymphocyte response to CMV and provide innovative methods to increase CMV-specific immunity. 

Altogether, HORUS will enhance personalised clinical prevention and the treatment of CMV disease, ultimately improving patient outcomes.